Management of heart failure with reduced ejection fraction in Europe: design of the ARIADNE registry

Management of heart failure with reduced ejection fraction in Europe: design of the ARIADNE registry

Abstract Aims The introduction of sacubitril/valsartan (an angiotensin receptor–neprilysin inhibitor) is likely to change the approach to the management of patients with chronic heart failure with reduced ejection fraction (HFrEF). The Assessment of Real Life Care–Describing European Heart Failure M...

Full description

Bibliographic Details
Main Authors: Uwe Zeymer, Andrew L. Clark, Vivencio Barrios, Thibaud Damy, Jaroslaw Drożdż, Candida Fonseca, Lars H. Lund, Gabriele Di Comite, Stephan Hupfer, Aldo P. Maggioni
Format: Article
Language:English
Published: Wiley 2020-04-01
Series:ESC Heart Failure
Subjects:
Sacubitril/valsartan
ARNI
Heart failure
Implementation
Heart failure with reduced ejection fraction
Real‐life data
Online Access:https://doi.org/10.1002/ehf2.12569

Internet

https://doi.org/10.1002/ehf2.12569

Similar Items